Compare Amylx Pharmaceuticals Inc (AMLX) vs Aterian Inc (ATER) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

Aterian (ATER) trades at $1.15, down 3.36% with a bullish technical signal despite negative profitability. Revenue has declined from $221M in 2022 to $69M in 2025, with net losses narrowing but persisting. The company is pursuing an asset sale, with proxy advisors recommending stockholders vote for transactions expected to return $0.85-$1.14 per share. Analyst sentiment is split evenly between Buy and Hold ratings.

The outlook hinges on the successful asset sale providing shareholder returns, but fundamental challenges remain with sustained losses and cash burn. Investment opportunity exists in the potential special dividend, while risks include ongoing operational losses and competitive pressures in consumer products.